Cargando…

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Heat shock protein 90 (HSP90) is a vital chaperone protein, regulating signaling pathways and correcting misfolded proteins in cancer cells by interacting with oncogenic client proteins and co-chaperones. The inhibition of HSP90 chaperone machinery has been demonstrated as a potential approach with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zi-Nan, Luo, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685368/ https://www.ncbi.nlm.nih.gov/pubmed/36367182 http://dx.doi.org/10.3892/or.2022.8443

Ejemplares similares

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Targeting Hsp90 in urothelial carcinoma
por: Chehab, Mahmoud, et al.
Publicado: (2015)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

The chaperone system in cancer therapies: Hsp90
por: Basset, Charbel A., et al.
Publicado: (2023)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance
por: Zhang, Jian, et al.
Publicado: (2022)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90
por: Alberti, Giusi, et al.
Publicado: (2022)

The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases
por: Qi, Shiyu, et al.
Publicado: (2022)

Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases
por: Tukaj, Stefan, et al.
Publicado: (2022)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Khajapeer, Kalubai Vari, et al.
Publicado: (2015)

Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
por: Park, Sangkyu, et al.
Publicado: (2019)

Molecular Dynamics Simulations of Hsp90 with an Eye to Inhibitor Design
por: Moroni, Elisabetta, et al.
Publicado: (2012)

The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
por: Chang, Cheng, et al.
Publicado: (2023)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?—A systematic review
por: Magyar, Christian Tibor Josef, et al.
Publicado: (2023)

Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer
por: Zagouri, Flora, et al.
Publicado: (2012)

Organismal Roles of Hsp90
por: van Oosten-Hawle, Patricija
Publicado: (2023)

Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded-Protein-Based Nanoformulation for Cancer Therapy
por: K. Rochani, Ankit, et al.
Publicado: (2020)

HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy
por: Lin, Tzu-yin, et al.
Publicado: (2016)

Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
por: Ardestani, Mina, et al.
Publicado: (2022)

Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
por: Pan, Xin, et al.
Publicado: (2022)

The Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases
por: Roberts, Richard J., et al.
Publicado: (2021)

Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know
por: Jay, Daniel, et al.
Publicado: (2022)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
por: CHENG, WEI, et al.
Publicado: (2015)

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
por: Kuroyanagi, Gen, et al.
Publicado: (2022)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1
por: Park, Hye-Kyung, et al.
Publicado: (2020)

Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms
por: Lu, Xiangyi, et al.
Publicado: (2012)

Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges
por: Piper, Peter W., et al.
Publicado: (2011)

HSP90 as a novel molecular target in non-small-cell lung cancer
por: Esfahani, Khashayar, et al.
Publicado: (2016)

Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins
por: Solár, Peter, et al.
Publicado: (2011)

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
por: Woodford, Mark R., et al.
Publicado: (2016)

Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance
por: Shahinas, Dea, et al.
Publicado: (2013)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0tfoal59hrn9l9d0htva12tup